July/August 2026 Newsletter



Simplified O-Glycan Release with Orela

The **LudgerLiberate Orela Glycan Release Kit** (**LL-ORELA-A2**) is a novel product that uses a proprietary reagent to cleave O-linked glycans from glycoproteins in a **mildly and selectively**. The released glycans have **free-reducing termini** that allow fluorescent tagging by reductive amination. The kit contains reagents and materials for up to **12 samples** and can be used with biopharmaceutical glycoproteins of various types and sources.

The **advantages** of LudgerLiberate Orela Glycan Release Kit are as follows:

- It is **compatible with complex and sialylated O-linked glycans**, unlike O-glycosidase.
- It **preserves the native structure of the glycoprotein backbone**, unlike hydrazinolysis.
- It is **fast and easy to use**, requiring only a few hours of incubation and minimal sample preparation.

Follow the workflow below to **release the O-linked glycans in your therapeutic glycoprotein** sample.



Orela Reagent	Incubation	Cooling	Drying	Acidification	Clean-Up
Add 200 µl of Orela relase agent to a pure and dried sample	5-16 hrs @50°C	@Room Temperature	Centrifugal evaporation @30-40°C	200 µl of 50% Acetic Acid @4°C overnight	LudgerClean CEX cartridges

The resulting samples can then be **fluorescently labelled** and **analysed using HPLC**, **CE** or **MS**. If you require any further information, please contact us at **info@ludger.com**.

Join our Glycotechnology News Service

Subscribe

Trusted Enzymes for Complete Glycan Analysis

For over two decades, **Ludger** and **QA-Bio** have partnered to deliver high-quality, reliable solutions for glycan analysis. This long-standing collaboration brings together deep expertise and a shared commitment to supporting scientists with tools they can trust. Today, Ludger proudly offers a comprehensive range of QA-Bio enzymes, designed to support every stage of glycan characterisation workflows.

From efficient glycan release using industry-standard **PNGase F** and convenient CarboRelease kits, to detailed structural analysis with **Endoglycosidase F** variants and **Endoglycosidase H**, these enzymes provide the precision required for accurate and reproducible results. Complementing this are highly specific **exoglycosidases**, enabling stepwise glycan sequencing and fine structural elucidation.

Whether you are working in biopharmaceutical development, quality control, or academic research, this integrated portfolio simplifies complex workflows and enhances confidence in your data. By combining Ludger's analytical expertise with QA-Bio's enzyme excellence, researchers gain access to a seamless toolkit for glycomics studies.

Explore the full range of **QA-Bio enzymes available through Ludger** and discover how our trusted partnership continues to support innovation in glycoscience.

Ludger Highlights GlycoTechnology Innovation @ 95th Harden Conference

Dr Daniel Spencer (Head of Development) recently presented at the 95th Harden Conference with a talk titled **"From Glycan Discovery to Clinical Diagnostics: Are We Ready to Translate Glycomics?"**, highlighting the growing potential of glycoscience to support future advances in diagnostics, biotechnology, and healthcare.

Ludger continues to advance the development and application of glycan analysis technologies, supporting researchers and organisations seeking better to understand the complex role of glycosylation in biological systems. Recent work from the Ludger team demonstrates the company's capabilities in glycopeptide mapping, delivering detailed insights into glycan structures and their relationship to protein biology, including the analysis of immunoglobulin G (IgG), a widely studied glycoprotein model for understanding glycosylation patterns and biological function.

By combining specialist glycan science with advanced analytical capabilities, Ludger supports customers in generating meaningful data from complex biological samples, enabling applications across biopharmaceutical development, biomarker research, and next-generation therapeutic discovery. Through its analytical services, technical collaborations, and future technology development initiatives, Ludger continues to work with partners to advance innovative glyco-technology solutions and address evolving challenges in biotechnology and healthcare.

If your organisation's vision and objectives align with ours, we would like to invite you to collaborate with us to develop innovative glycomics solutions! Please register your interest and contact us at **info@ludger.com**. We look forward to hearing from you.

Join our Glycotechnology News Service

Subscribe